Key Points
- AxoGen director Kathy Johnson Weiler sold 14,150 shares for approximately $641,000 at an average price of $45.30 under a pre-arranged Rule 10b5-1 trading plan.
- AxoGen reported quarterly revenue of $69.73 million and earnings per share of $0.12, matching analyst EPS expectations while exceeding revenue estimates. Analysts expect a full-year loss of $0.45 per share.
- Analyst sentiment remains favorable, with a consensus rating of “Moderate Buy” and a $51 target price; nine of 11 analysts rate the stock a Buy. AXGN recently opened at $48.48, near its 52-week high of $49.12.
AxoGen, Inc. (NASDAQ:AXGN - Get Free Report) Director Kathy Johnson Weiler sold 14,150 shares of AxoGen stock in a transaction on Friday, August 7th. The shares were sold at an average price of $45.30, for a total transaction of $640,995.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
AxoGen Price Performance
AXGN stock opened at $48.48 on Wednesday. The stock has a market capitalization of $2.61 billion, a PE ratio of -71.29 and a beta of 1.11. The company's 50-day moving average is $43.01 and its 200-day moving average is $38.14. The company has a debt-to-equity ratio of 0.07, a current ratio of 6.60 and a quick ratio of 5.04. AxoGen, Inc. has a 1 year low of $13.64 and a 1 year high of $49.12.
AxoGen (NASDAQ:AXGN - Get Free Report) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.12 EPS for the quarter, meeting analysts' consensus estimates of $0.12. AxoGen had a negative return on equity of 8.90% and a negative net margin of 13.36%.The business had revenue of $69.73 million during the quarter, compared to analyst estimates of $67.10 million. Equities research analysts expect that AxoGen, Inc. will post -0.45 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of equities analysts have recently weighed in on the company. Canaccord Genuity Group upped their target price on AxoGen from $50.00 to $55.00 and gave the stock a "buy" rating in a research report on Thursday, July 30th. Lake Street Capital boosted their price target on shares of AxoGen from $40.00 to $50.00 and gave the company a "buy" rating in a research note on Thursday, April 23rd. Jefferies Financial Group restated a "buy" rating and set a $55.00 price target on shares of AxoGen in a research note on Wednesday, July 29th. Weiss Ratings restated a "sell (d-)" rating on shares of AxoGen in a report on Friday, May 29th. Finally, HC Wainwright raised their price objective on shares of AxoGen from $50.00 to $53.00 and gave the company a "buy" rating in a research note on Thursday, July 30th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, AxoGen currently has a consensus rating of "Moderate Buy" and a consensus target price of $51.00.
Read Our Latest Report on AXGN
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the stock. Royal Bank of Canada boosted its position in shares of AxoGen by 14.2% during the first quarter. Royal Bank of Canada now owns 38,043 shares of the medical equipment provider's stock valued at $704,000 after buying an additional 4,723 shares during the last quarter. AQR Capital Management LLC raised its position in AxoGen by 45.3% in the 1st quarter. AQR Capital Management LLC now owns 23,917 shares of the medical equipment provider's stock valued at $442,000 after buying an additional 7,453 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in AxoGen by 4.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 25,185 shares of the medical equipment provider's stock valued at $466,000 after buying an additional 1,057 shares during the last quarter. Jones Financial Companies Lllp lifted its stake in AxoGen by 104,810.0% during the 1st quarter. Jones Financial Companies Lllp now owns 10,491 shares of the medical equipment provider's stock valued at $194,000 after acquiring an additional 10,481 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in AxoGen by 37.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 379,070 shares of the medical equipment provider's stock valued at $4,113,000 after acquiring an additional 103,072 shares in the last quarter. Institutional investors own 80.29% of the company's stock.
AxoGen Company Profile
(
Get Free Report)
AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen's offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.
The company's core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
